ScreenerHero

XERS Xeris Biopharma Holdings, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · xerispharma.com
10.13USD+11.56%Mkt Cap: 1.85B $P/E: —

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-u…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap1.85B USD
Enterprise Value1.82B USD
Revenue (TTM)335.41M USD
Gross Profit249.28M USD
Net Income (TTM)554.00K USD
Revenue/Share1.99 USD
Last Price10.13 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees435
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)23.28
PEG—
EV/EBITDA37.38
EV/Revenue5.44
P/S4.94
P/B-162.14
EPS (TTM)-0.10
EPS (Forward)0.39
52W Range
5.25080% of range11.33
52W High11.33 USD
52W Low5.250 USD
Profitability
Gross Margin85.41%
Oper. Margin5.62%
EBITDA Margin14.54%
Profit Margin0.19%
ROE4.05%
ROA0.14%
Growth
Revenue Growth28.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF28.63M USD
CapEx (TTM)696.00K USD
FCF Margin15.64%
FCF Yield2.84%
Net Debt167.69M USD
Net Debt/EBITDA3.44
Balance Sheet
Debt/Equity18.85
Current Ratio1.45
Quick Ratio0.95
Book Value/Sh-0.06 USD
Cash/Share0.67 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.29 USD
Upside (mean)+21.3%
Target Range8.000 USD – 18.00 USD
8.000+21.3% to mean18.00
# Analysts7
Ownership
Shares Out.182.32M
Float176.03M
Insiders3.05%
Institutions60.12%
Short Interest
Short Ratio5.1d
Short % Float4.57%
Short % Out.4.42%
Shares Short8.06M
Short (prev mo.)8.73M
Technical
SMA 508.458 (+19.8%)
SMA 2007.197 (+40.8%)
Beta0.85
S&P 52W Chg14.58%
Avg Vol (30d)2.44M
Avg Vol (10d)4.24M
Technical Indicators
RSI (14)66.4
MACD0.3782
MACD Signal0.2422
MACD Hist.+0.1361
BB Upper10.34 USD
BB Middle8.677 USD
BB Lower7.019 USD
BB Width38.22%
ATR (14)0.5952 USD
Vol Ratio (20d)1.52x